Regulation of TLR Signaling and Innate Immunity by RP105

RP105 对 TLR 信号传导和先天免疫的调节

基本信息

  • 批准号:
    7897636
  • 负责人:
  • 金额:
    $ 36.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-07-01 至 2012-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Toll-like receptors (TLRs) are signaling receptors that are central to innate immune recognition of a variety of pathogens. Activation of TLR signaling by conserved microbial structures promotes the induction of innate immune responses. Such responses must be kept under tight control. Responses that are disrupted, delayed, or of insufficient vigor can lead to a failure to control infection. On the other hand, excessive or inappropriate inflammation can be harmful or even fatal- something seen in the hyper-activation of innate immune responses that marks microbial sepsis. Innate immune dysregulation is thought to be central to the pathogenesis of the diseases caused by diverse Category A and B biological threat agents. Conversely, well-regulated innate immune responses are thought to be key to successful host responses to these pathogens, as well as to successful vaccination against these and other infectious agents. Signaling through TLRs is tightly regulated. We recently discovered a novel mechanism of TLR counter- regulation- the TLR4 homolog, RP105. We have found that: (a) RP105 expression mirrors that of TLR4 on antigen presenting cells; (b) RP105 is a specific inhibitor of TLR4 signaling in HEK293 cells; (2) RP105 interacts directly with TLR4, inhibiting the ability of the TLR4 signaling complex to bind lipopolysaccharide (LPS); (3) RP105 regulates TLR4 signaling in dendritic cells and macrophages; (4) RP105 regulates in vivo responses to LPS; and (5) RP105 acts as a biologically important inhibitor of TLR4 signaling in both microbial and non-microbial models of inflammation. The central hypothesis underlying these studies is that RP105 is a physiological regulator of TLR4 signaling and TLR4-driven immune responses. The long-term goal of this work is to define the molecular mechanisms that underlie the generation and regulation of successful immune responses to biological threat agents and other pathogens. The studies in this proposal will characterize, both in vitro and in vivo, the capacity of RP105 to modulate TLR signaling and TLR-driven immune responses. We will: (1) Define the molecular mechanisms and biological consequences of RP105- mediated modulation of TLR signaling in myeloid cells; (2) Determine the mechanisms responsible for modulation of B cell function by RP105; and (3) Define the role of RP105 in regulating TLR4 signaling in response to endogenous ligands.
描述(由申请人提供):Toll样受体(TLR)是对多种病原体的先天免疫识别至关重要的信号传导受体。通过保守的微生物结构激活TLR信号传导促进先天免疫应答的诱导。必须严格控制这种反应。反应中断,延迟或活力不足可能导致无法控制感染。另一方面,过度或不适当的炎症可能是有害的,甚至是致命的-这在先天免疫反应的过度激活中可以看到,标志着微生物败血症。先天性免疫失调被认为是由不同的A类和B类生物威胁因子引起的疾病的发病机制的中心。相反,良好调节的先天免疫应答被认为是宿主对这些病原体的成功应答以及针对这些和其他感染因子的成功疫苗接种的关键。通过TLR的信号传导受到严格调控。我们最近发现了一种新的TLR反调节机制--TLR 4同系物RP 105。我们发现:(a)RP 105的表达反映了抗原呈递细胞上TLR 4的表达;(B)RP 105是HEK 293细胞中TLR 4信号传导的特异性抑制剂;(2)RP 105直接与TLR 4相互作用,抑制TLR 4信号传导复合物结合脂多糖(LPS)的能力;(3)RP 105调节树突状细胞和巨噬细胞中TLR 4信号传导;(4)RP 105调节对LPS的体内应答;和(5)RP 105在炎症的微生物和非微生物模型中充当TLR 4信号传导的生物学重要抑制剂。这些研究的核心假设是RP 105是TLR 4信号传导和TLR 4驱动的免疫应答的生理调节剂。这项工作的长期目标是确定产生和调节对生物威胁因子和其他病原体的成功免疫反应的分子机制。本提案中的研究将在体外和体内表征RP 105调节TLR信号传导和TLR驱动的免疫应答的能力。我们将:(1)确定RP 105介导的髓样细胞TLR信号转导调节的分子机制和生物学后果;(2)确定RP 105调节B细胞功能的机制;(3)确定RP 105在响应内源性配体调节TLR 4信号转导中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher L Karp其他文献

Getting to the core of the gut microbiome
触及肠道微生物组的核心
  • DOI:
    10.1038/nbt0409-344
  • 发表时间:
    2009-04-01
  • 期刊:
  • 影响因子:
    41.700
  • 作者:
    Matthias H Tschöp;Philip Hugenholtz;Christopher L Karp
  • 通讯作者:
    Christopher L Karp

Christopher L Karp的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher L Karp', 18)}}的其他基金

Allergenicity resulting from functional mimicry of the TLR complex
TLR 复合体的功能模仿导致过敏性
  • 批准号:
    7867274
  • 财政年份:
    2010
  • 资助金额:
    $ 36.42万
  • 项目类别:
MODULATION OF TISSUE INFLAMMATION BY RP105/TLR4
RP105/TLR4 对组织炎症的调节
  • 批准号:
    8098915
  • 财政年份:
    2010
  • 资助金额:
    $ 36.42万
  • 项目类别:
Allergenicity resulting from functional mimicry of the TLR complex
TLR 复合体的功能模仿导致过敏性
  • 批准号:
    8034306
  • 财政年份:
    2010
  • 资助金额:
    $ 36.42万
  • 项目类别:
Immunobiology of IFRD1, a gene modifying CF lung disease
IFRD1(一种改变 CF 肺病的基因)的免疫生物学
  • 批准号:
    7741410
  • 财政年份:
    2009
  • 资助金额:
    $ 36.42万
  • 项目类别:
Immunobiology of IFRD1, a gene modifying CF lung disease
IFRD1(一种改变 CF 肺病的基因)的免疫生物学
  • 批准号:
    7904958
  • 财政年份:
    2009
  • 资助金额:
    $ 36.42万
  • 项目类别:
MODULATION OF TISSUE INFLAMMATION BY RP105/TLR4
RP105/TLR4 对组织炎症的调节
  • 批准号:
    7650337
  • 财政年份:
    2008
  • 资助金额:
    $ 36.42万
  • 项目类别:
Regulation of TLR Signaling and Innate Immunity by RP105
RP105 对 TLR 信号传导和先天免疫的调节
  • 批准号:
    7650111
  • 财政年份:
    2007
  • 资助金额:
    $ 36.42万
  • 项目类别:
Regulation of TLR Signaling and Innate Immunity by RP105
RP105 对 TLR 信号传导和先天免疫的调节
  • 批准号:
    7455004
  • 财政年份:
    2007
  • 资助金额:
    $ 36.42万
  • 项目类别:
MODULATION OF TISSUE INFLAMMATION BY RP105/TLR4
RP105/TLR4 对组织炎症的调节
  • 批准号:
    7475899
  • 财政年份:
    2007
  • 资助金额:
    $ 36.42万
  • 项目类别:
Regulation of TLR Signaling and Innate Immunity by RP105
RP105 对 TLR 信号传导和先天免疫的调节
  • 批准号:
    7302729
  • 财政年份:
    2007
  • 资助金额:
    $ 36.42万
  • 项目类别:

相似海外基金

Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
  • 批准号:
    10751133
  • 财政年份:
    2023
  • 资助金额:
    $ 36.42万
  • 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
  • 批准号:
    10696138
  • 财政年份:
    2022
  • 资助金额:
    $ 36.42万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10663066
  • 财政年份:
    2022
  • 资助金额:
    $ 36.42万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10537159
  • 财政年份:
    2022
  • 资助金额:
    $ 36.42万
  • 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
  • 批准号:
    21K08723
  • 财政年份:
    2021
  • 资助金额:
    $ 36.42万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10156950
  • 财政年份:
    2021
  • 资助金额:
    $ 36.42万
  • 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
  • 批准号:
    10631854
  • 财政年份:
    2021
  • 资助金额:
    $ 36.42万
  • 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
  • 批准号:
    10153927
  • 财政年份:
    2021
  • 资助金额:
    $ 36.42万
  • 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10331830
  • 财政年份:
    2021
  • 资助金额:
    $ 36.42万
  • 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
  • 批准号:
    20K16294
  • 财政年份:
    2020
  • 资助金额:
    $ 36.42万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了